wet Age related Macular Degeneration. Degeneration of macula and posterior pole
Conditions
Interventions
Intervention 1: Control group: placebo capsules, will be given twice a day for 4 months in addition to standard treatment according to Treat and Extend Regimen. In this regimen, All subjects will rec
Placebo
Treatment - Drugs
Control group: placebo capsules, will be given twice a day for 4 months in addition to standard treatment according to Treat and Extend Regimen. In this regimen, All subjects will receive 1.25 mg int
Intervention group 1: in this group, patients will take Doxycycline, 100 mg cap, twice a day, in addition to standard treatment according to Treat and Extend Regimen for 4 months. All subjects will re
Intervention group 2: in this group, patients will take Doxycycline, 100 mg cap, twice a day until the completion of induction phase of Treat and Extend Regimen protocol in addition to standard treatm
Sponsors
Vice Chancellor for Research and Technology, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: occult choroidal neovascularization (classic CNV); subfoveal age related macular degeneration; naïve patients; central retinal thickness plus subfoveal fluid = 500 µm; lesion size = 2 Disk Diameter; no history for neither systemic disease nor myocardial infarction Exclusion criteria: vitreomacular adhesion; fibrovascular scar; geographic atrophy; history of intraocular pressure rise.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Induction time. Timepoint: monthly after initiation of intervention. Method of measurement: Questionnaire.;Number of needed injections to complete Induction phase. Timepoint: monthly after initiation of intervention. Method of measurement: Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Final Best Corrected Visual Acuity (BCVA). Timepoint: 12 months after initiation of intervention. Method of measurement: Early Treatment Diabetic Retinopathy Study (ETDRS) charts.;Size of neovascularization. Timepoint: 12 months after initiation of intervention. Method of measurement: Questionnaire.;Foveal thickness. Timepoint: 12 months after initiation of intervention. Method of measurement: Questionnaire, Optical Coherence Tomography (OCT) records.;Relapse: new onset of Intraretinal fluid, Subretinal fluid, Hemorrhage or decrease of BCVA more than 5 scores). Timepoint: 12 months after initiation of intervention. Method of measurement: Questionnaire: physical examination, OCT scan, ETDRS Charts. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactPourya Azimi
Student's Scientific Research Center of Tehran University of Medical Sciences
Outcome results
None listed